Neurocrine Biosciences (NBIX): Reiterating Overweight Ahead Of Tourette’s Results - Piper Jaffray

September 22, 2016 7:01 AM EDT Send to a Friend
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Neurocrine Bio. (NASDAQ: NBIX) ahead of regulatory progress ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login